If you’re considering GLP-1 medication for weight loss, you’ve probably run into this question: semaglutide or tirzepatide?

They’re the two dominant options. Semaglutide is the molecule in Wegovy and Ozempic. Tirzepatide powers Zepbound and Mounjaro. Both produce significant weight loss. Both are weekly injections. Both have waiting lists and billion-dollar marketing budgets behind them.

But they’re not the same drug. They work differently, they’ve produced different results in clinical trials, and they come with their own trade-offs. Here’s what the science actually says.

How Each One Works

Semaglutide: Single-Target Approach

Semaglutide is a GLP-1 receptor agonist. That means it mimics a single gut hormone: glucagon-like peptide-1.

Here’s what GLP-1 does in your body:

Slows gastric emptying — food moves through your stomach more slowly, so you feel full longer
Signals satiety to your brain — reduced appetite and fewer cravings
Stimulates insulin secretion — helps regulate blood sugar after meals
Suppresses glucagon — reduces the liver’s glucose output

Natural GLP-1 breaks down in your body within minutes. Semaglutide is engineered to last about a week, which is why it’s a once-weekly injection.

If you’re new to GLP-1 medications altogether, our beginner’s guide covers the fundamentals.

Tirzepatide: Dual-Target Approach

Tirzepatide is a “twincretin” or dual GIP/GLP-1 receptor agonist. It mimics two gut hormones instead of one:

GLP-1 — same effects as described above
GIP (glucose-dependent insulinotropic polypeptide) — an additional hormone that enhances insulin secretion, may improve fat metabolism, and appears to amplify the appetite-suppressing effects of GLP-1

The addition of GIP activity is what makes tirzepatide different. It’s not just “stronger semaglutide.” It’s working on a different biological pathway that produces additive effects on appetite, blood sugar control, and weight loss.

Think of it this way: semaglutide is pushing one lever. Tirzepatide is pushing two.

Clinical Trial Results: The Numbers

This is where it gets interesting. Both drugs have been studied in large, well-designed clinical trials published in the New England Journal of Medicine.

Semaglutide: The STEP Trials

The STEP 1 trial (Wilding et al., 2021) studied semaglutide 2.4mg in adults with obesity:

Participants: 1,961 adults, BMI 30+ (or 27+ with comorbidities)
Duration: 68 weeks
Average weight loss: 14.9% of body weight (vs. 2.4% with placebo)
Participants losing 10%+: 69.1%
Participants losing 15%+: 50.5%
Participants losing 20%+: 32.0%

Those results were groundbreaking when they were published. Nearly 15% body weight loss from a once-weekly injection was unprecedented for a pharmaceutical intervention.

Tirzepatide: The SURMOUNT Trials

The SURMOUNT-1 trial (Jastreboff et al., 2022) studied tirzepatide at three doses in adults with obesity:

Participants: 2,539 adults, BMI 30+ (or 27+ with comorbidities)
Duration: 72 weeks
Average weight loss at 15mg dose: 22.5% of body weight (vs. 2.4% with placebo)
Average weight loss at 10mg dose: 21.4%
Average weight loss at 5mg dose: 16.0%
Participants losing 20%+ (15mg): 56.7%
Participants losing 25%+ (15mg): 39.7%

Tirzepatide at the highest dose produced about 50% more weight loss than semaglutide. Even the lowest tirzepatide dose (5mg) outperformed semaglutide 2.4mg by about 1 percentage point.

Direct Comparison Caveat

Here’s what you need to know about these numbers: the STEP and SURMOUNT trials weren’t direct head-to-head comparisons. They were separate trials with different participant pools, run at different times, with slightly different durations (68 vs. 72 weeks).

A true head-to-head trial (SURMOUNT-5) has been completed and the results are expected in early-to-mid 2026. Preliminary data suggests tirzepatide maintains its advantage, but we don’t have final published results to cite yet.

What the current data tells us: Tirzepatide likely produces more weight loss than semaglutide. The magnitude of the difference (roughly 5-8 percentage points) is clinically meaningful. But individual responses vary enormously. Some people lose 30% on semaglutide. Some lose 10% on tirzepatide.

Side Effect Comparison

Both medications share similar side effects because they both activate GLP-1 receptors. The gastrointestinal effects are the most common.

Common Side Effects (from clinical trials)

Side Effect	Semaglutide 2.4mg	Tirzepatide 15mg
Nausea	44.2%	44.4%
Diarrhea	30.0%	33.4%
Vomiting	24.8%	25.3%
Constipation	24.2%	23.0%
Abdominal pain	14.2%	14.0%
Headache	14.4%	11.8%
Fatigue	11.0%	9.2%

The side effect profiles are remarkably similar. Nausea rates are nearly identical at about 44%. GI symptoms in general are a wash between the two drugs.

The important context: These percentages represent people who experienced the side effect at any point during the trial. Most side effects are worst during the dose escalation phase (first 3-4 months) and improve significantly once you reach your maintenance dose.

For a full guide on managing these side effects, see our GLP-1 side effects guide.

Serious Side Effects (Rare)

Both medications carry warnings for:

Pancreatitis: Rare (less than 1% in trials) but serious. Symptoms include severe abdominal pain radiating to the back.
Gallbladder problems: Higher incidence with GLP-1 medications, likely related to rapid weight loss rather than the drug itself.
Thyroid C-cell tumors: Boxed warning based on animal studies. Not confirmed in humans, but people with a personal or family history of medullary thyroid carcinoma should not use either medication.
Hypoglycemia: Rare when used alone. More common when combined with insulin or sulfonylureas.

Neither drug has shown a clear safety advantage over the other for serious side effects based on available data.

Dosing Schedules

Both are weekly injections, but the escalation schedules differ.

Semaglutide (Wegovy) Dose Escalation

Weeks	Dose
1-4	0.25mg
5-8	0.5mg
9-12	1.0mg
13-16	1.7mg
17+	2.4mg (maintenance)

Time to maintenance dose: 16 weeks (4 months)

Tirzepatide (Zepbound) Dose Escalation

Weeks	Dose
1-4	2.5mg
5-8	5.0mg
9-12	7.5mg
13-16	10.0mg
17-20	12.5mg
21+	15.0mg (max dose)

Time to max dose: 20 weeks (5 months)

Tirzepatide has a longer escalation schedule with more steps. Your provider may keep you at a lower maintenance dose (7.5mg or 10mg) if you’re seeing good results, rather than pushing to the max 15mg dose.

Why escalation matters: Starting at a low dose and gradually increasing is how you minimize side effects. Providers who jump you straight to a high dose are cutting corners, and you’ll pay for it with worse nausea and GI symptoms.

Pricing Comparison

Brand-Name (Without Insurance)

	Monthly Cost	Annual Cost
Wegovy (semaglutide)	~$1,349	~$16,188
Zepbound (tirzepatide)	~$1,060	~$12,720

Interesting twist: brand-name tirzepatide is actually cheaper than brand-name semaglutide. Eli Lilly (Zepbound’s manufacturer) has been pricing aggressively to gain market share.

Compounded (Cash-Pay Through Telehealth)

	Monthly Range	Annual Range
Semaglutide	$99-349/mo	$1,188-4,188
Tirzepatide	$149-399/mo	$1,788-4,788

Compounded tirzepatide typically runs $50-100 more per month than compounded semaglutide at equivalent points in the dose escalation. This is because tirzepatide API is more expensive for compounding pharmacies to source.

For the cheapest options across providers, see our pricing comparison.

Which Providers Offer Which?

Most telehealth providers offer both, but some specialize:

Both semaglutide and tirzepatide:

Remedy Meds (full review)
Found
Ro
TMRW
Noom Med

Primarily semaglutide:

Some budget-focused providers only carry semaglutide to keep costs down

Brand-name through insurance:

Sequence (Wegovy and Zepbound)
PlushCare (prescribes both to your pharmacy)
Form Health (both, insurance-dependent)

Browse all options on our clinic comparison page.

Who Should Choose Which?

Semaglutide might be better if:

Budget is tight. It’s $50-100/month cheaper compounded, and the savings add up over a year-long treatment course.
You want more long-term safety data. Semaglutide has been on the market longer (FDA-approved for weight loss in 2021 vs. 2023 for tirzepatide). There’s simply more real-world data on long-term use.
You have cardiovascular concerns. The SELECT trial showed semaglutide reduces cardiovascular events by 20% in overweight/obese adults with existing heart disease. Tirzepatide hasn’t completed an equivalent cardiovascular outcomes trial yet.
Your insurance covers Wegovy but not Zepbound. Coverage varies by plan, and some formularies include one but not the other.

Tirzepatide might be better if:

You want maximum weight loss. The clinical data consistently shows more weight loss with tirzepatide, roughly 5-8 percentage points more than semaglutide.
You have significant insulin resistance or type 2 diabetes. The dual GIP/GLP-1 mechanism may provide better blood sugar control for people with insulin-related metabolic issues.
Semaglutide isn’t producing enough results. Some people plateau on semaglutide at 10-12% weight loss. Switching to tirzepatide can break through that plateau.
Your provider recommends it based on your profile. Clinicians may have a preference based on your specific metabolic picture, comorbidities, and treatment goals.

Either one works if:

You don’t have a strong reason to prefer one over the other
Your provider offers both and you trust their clinical judgment
Budget isn’t a deciding factor

What About Switching Between Them?

Yes, you can switch. It’s not uncommon. People switch for several reasons:

Plateaued weight loss on semaglutide, want to try tirzepatide
Side effects that are better tolerated with one vs. the other
Cost changes (insurance adds or drops coverage for one)
Supply shortages affecting availability

Your provider will typically reset your dosing when you switch. You won’t start tirzepatide at 15mg just because you were on semaglutide 2.4mg. Expect to go through dose escalation again, though possibly on a faster schedule if you tolerated the first medication well.

Frequently Asked Questions

Can I take both at the same time?

No. These medications should not be combined. They activate overlapping receptor pathways, and combining them would likely amplify side effects without proportional benefits.

How quickly will I see results?

Most people notice appetite reduction within the first 1-2 weeks on either medication. Measurable weight loss typically shows up by weeks 4-8. The full effect builds over 6-12 months as you escalate to maintenance dosing.

Is one better for keeping weight off long-term?

Both medications require ongoing use to maintain results. Studies show that most people regain weight after stopping either semaglutide or tirzepatide. There’s no current evidence that one has better long-term weight maintenance than the other.

What if neither works for me?

About 10-15% of people in clinical trials were classified as “non-responders,” meaning they lost less than 5% of body weight. If one medication doesn’t work, trying the other is reasonable since they have different mechanisms. Beyond that, your provider may discuss combination approaches or alternative treatments.

Are there oral versions?

Oral semaglutide exists (Rybelsus) and is FDA-approved for type 2 diabetes. An oral weight-loss version is in late-stage trials. Oral tirzepatide is also in clinical development. Neither oral option is widely available for weight loss as of early 2026.

Which one has fewer injection site reactions?

Both are well-tolerated at the injection site. In clinical trials, injection site reactions (redness, itching, swelling) occurred in less than 5% of participants for both drugs. This shouldn’t be a deciding factor.

The Bottom Line

If you’re optimizing for maximum weight loss and can afford the slightly higher cost, tirzepatide has the edge. The SURMOUNT data showing 22.5% body weight loss is hard to argue with.

If you want the most established option with robust long-term data and cardiovascular benefits, semaglutide is the safer bet in terms of track record.

But here’s what matters most: either one produces life-changing weight loss for the majority of people who take it. The difference between 15% and 22% matters less than the difference between “I’m on treatment” and “I’m still thinking about it.”

Talk to a provider. Pick one. Start. You can always adjust later.

For help choosing a provider, read our guide to selecting a GLP-1 provider, or compare options head-to-head on our comparison page.

Semaglutide vs Tirzepatide: Which Works Better?